Another study by Lealem et al. from Jima university hospital (Ethiopia) reported a prevalence of moderate to severe anemia in 27.8% with a higher rate of mild anemia occurring in 72.2% of patients who were on HAART [15]; while a study in Nigeria recorded an overall prevalence of anemia in 51.15% of HAART experienced patients and by WHO toxicity grading, grade 2-4(Hb=9.5 to <6.5g/dl) contributed the most of the anemic patients (>49%)[8]. This evidence concerns the gene GSTM1 and anemia (phenotype).